Company: HCTI
Filing Date: 2025-10-14
Form Type: DEF 14C
Source: 0001213900-25-098801
Chunk: 2

Company: Healthcare Triangle, Inc.
Filing Date: 2025-10-14
Form: DEF 14C
Chunk 2
---
 of the Exchange Act, to the holders of record as September 19, 2025 (the “ Record Date”) of outstanding shares of common stock of Healthcare Triangle, Inc., a Delaware corporation (“ Healthcare Triangle,” the “ Company,” “ we,” “ our,” or “ us”), to notify the shareholders that, on September 19, 2025, the Company received the written consent in lieu of a meeting of stockholders from Suresh Venkatachari, the holder of 81.82% of the Company’s outstanding voting power (the “ Majority Stockholder”), approving the issuance of 1,388,041shares of the Company’s restricted common stock (the “ Acquisition Shares”) to Niyama Healthcare, Inc., a Delaware corporation and provider of Mental Health and Hospital Information Systems technology, across India, South East Asia, and Europe (the “ Seller”), pursuant to an Asst Transfer Agreement dated June 16, 2025 and amended on August 28, 2025, as partial consideration for the acquisition (the “ Acquisition”) by the Company of (i) all of the Seller’s assets related to its cloud and technology domain business and (ii) 100% of the equity of interest in Ezovion Solutions Private Limited, a Hospital Information Systems SaaS Provider in Chennai, India. The other consideration paid or payable by the Company includes: (1) $1.5 million in cash, of which $1.2 million was due at the closing of the Acquisition and $300,000 to be paid at the later of the satisfaction of certain withholding requirements or within 120 days of the closing and (2) up to $1.2 million in earn -outpayments contingent on first -yearfinancial performance targets to be agreed upon within 90 days of the closing of the Acquisition. As described more fully in this Information Statement, stockholder approval of the issuance of the Acquisition Shares is required by Nasdaq Listing Rule 5635(a)(2). The Majority Stockholder approved the issuance of the Acquisition Shares on September 19, 2025. Our board of directors is not soliciting your consent or your proxy in connection with this action and neither consents nor proxies are being requested from stockholders. No further action of shareholders is required in connection with the approval of the issuance of the Acquisition Shares. This Information Statement is furnished solely for the purpose of informing our shareholders, in the manner required by the Exchange Act and Section 228(e) of the GCL, of the action taken by